This page shows the latest CAR-T therapy news and features for those working in and with pharma, biotech and healthcare.
Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being ... In addition, Oncology Newco will
Gilead eyes new first-line indication for CAR T Yescarta. ... Gilead’s Kite division presented new phase 2 data for its CAR T therapy Yescarta at ASH 2020 in relapsed or refractory high-risk large B-cell lymphoma (LBCL), a potential
Inspection of third-party manufacturing plant delayed due to COVID-19. The US Food and Drug Administration (FDA) has delayed a crucial decision for Bristol Myers Squibb’s CAR-T therapy ... BMS also agreed similar conditional payments, dependent on
Myer Squibb and bluebird bio’s submission for their CAR-T immunotherapy ide-cel has finally been accepted by the agency. ... Ide-cel has been awarded a Priority Medicines (PRIME) designation by the European Medicines Agency (EMA), and BMS and bluebird
Sales of its Kite-partnered CAR-T cell therapy Yescarta (axicabtagene ciloleucel) climbed to $156m in the quarter, an increase on the $120m it generated for the same period in 2019.
Novel CAR-T therapy targets heavily pre-treated myeloma. Bristol-Myers Squibb and bluebird bio have announced the resubmission of a new biologics license application (BLA) to the US Food and ... BMS/bluebird could face competition from another CAR-T
More from news
Approximately 15 fully matching, plus 91 partially matching documents found.
Examining three entirely different approaches to CAR-T therapy, it is possible to see just how much space there is for this exciting sector, therefore displaying the case for continued investment. ... Innovative CAR-T therapy demonstrates the depth of
Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... It now has more than 300 CAR-T clinical trials underway and collaboration with European and
It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships
This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma
More from intelligence
Approximately 1 fully matching, plus 23 partially matching documents found.
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
In a nutshell, CAR-T therapy involves extracting T-cells (a type of white blood cells that play a key role in immune response) from the patient, genetically engineering them to ... However, due to its novelty, it was difficult to access patients who have
SpaceX is inspiring people in a way that NASA hasn’t managed in over 30 years. ... Today’s therapy advances, such as CAR-T and gene therapy, are just as exciting and will help shape our world in the years to come.
CAR-T cell therapy costs close to $500, 000 per patient in the US, and 300, 000 in Europe. ... Zolgensma, gene therapy for the treatment of spinal muscular atrophy, is (at the time of writing) the most expensive drug in the world at $2.1m.
In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.
Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it. ... It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach.
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...